Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR6390 in Advanced Melanoma
NCT02671513Phase 1Unknown
- Sponsor
- Hengrui
- Start
- Jan 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dalpiciclib in melanoma, sponsored by Hengrui. Primary endpoint: Maximum Tolerated Dose at 3 weeks. Status: unknown.
02
Drugs
dalpiciclib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02671513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02671513.